Dr. Ashley L. Sumrall

Hematology | Oncology
1021 Morehead Medical Drive, Suite 6100, 
Charlotte, NC 
On Staff At
Accepting New Patients
Offers Telehealth
1021 Morehead Medical Drive, Suite 6100, 
Charlotte, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ashley Sumrall is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Sumrall is rated as an Experienced provider by MediFind in the treatment of Sclerosing Mesenteritis. Her top areas of expertise are Glioma, Brain Tumor, Astrocytoma, and Glioblastoma. Dr. Sumrall is currently accepting new patients.

Her clinical research consists of co-authoring 35 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
The University Of Mississippi
Residency
The University of Mississippi
Specialties
Hematology
Oncology
Licenses
Internal Medicine in NC
Board Certifications
American Board Of Internal Medicine
American Board Of Internal Medicine, Medical Oncology
Fellowships
Duke University
Hospital Affiliations
Carolinas Medical Center-Northeast
Atrium Health Pineville
Carolinas Medical Center/behav Health
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Atrium Health Levine Cancer Institute (Medical Oncology & Immunotherapy)
1021 Morehead Medical Drive, Suite 6100, Charlotte, NC 28204

Additional Areas of Focus

Dr. Sumrall has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Pituitary Tumor
Thyroid Cancer
Neurofibromatosis Type 1 (NF1)
Ovarian Cancer
Breast Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Genomically-Guided Treatment Trial in Brain Metastases
Genomically-Guided Treatment Trial in Brain Metastases
Enrollment Status: Suspended
Publish Date: December 12, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Paxalisib, Entrectinib
Study Phase: Phase 2
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 02, 2025
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
A Phase II, Open-label Study of ONC201 in Adults With Recurrent High-grade Glioma
A Phase II, Open-label Study of ONC201 in Adults With Recurrent High-grade Glioma
Enrollment Status: Terminated
Publish Date: July 28, 2025
Intervention Type: Drug
Study Drug: ONC201
Study Phase: Phase 2
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Enrollment Status: Completed
Publish Date: May 11, 2023
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Depatuxizumab
Study Phase: Phase 3
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Enrollment Status: Terminated
Publish Date: March 23, 2023
Intervention Type: Drug, Other
Study Phase: Phase 2
View 6 Less Clinical Trials

35 Total Publications

Correction: Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
Correction: Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
Journal: Cancer discovery
Published: January 30, 2025
Similar Doctors
Experienced in Sclerosing Mesenteritis
Dr. Michael B. Livingston
Oncology | Hematology Oncology
Experienced in Sclerosing Mesenteritis
Dr. Michael B. Livingston
Oncology | Hematology Oncology
15830 Ballantyne Medical Pl, Ste 200, 
Charlotte, NC 
 (10.3 miles away)
980-442-9600
Languages Spoken:
English
See accepted insurances

Michael Livingston is an Oncologist and a Hematologist Oncology provider in Charlotte, North Carolina. Dr. Livingston is rated as a Distinguished provider by MediFind in the treatment of Sclerosing Mesenteritis. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Myxoid Liposarcoma.

Experienced in Sclerosing Mesenteritis
Dr. Wenimar D. Salvador
Hematology Oncology | Hematology | Oncology
Experienced in Sclerosing Mesenteritis
Dr. Wenimar D. Salvador
Hematology Oncology | Hematology | Oncology

Blue Ridge Healthcare Medical Group Inc

720 Malcolm Blvd, 
Connelly Springs, NC 
 (53.7 miles away)
828-580-7536
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Wenimar Salvador is a Hematologist Oncology specialist and a Hematologist in Connelly Springs, North Carolina. Dr. Salvador is rated as a Distinguished provider by MediFind in the treatment of Sclerosing Mesenteritis. His top areas of expertise are Leukocytosis, Colorectal Cancer, Familial Colorectal Cancer, and Pleuropulmonary Blastoma. Dr. Salvador is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sumrall's expertise for a condition
ConditionClose
View All 13 Distinguished Conditions
View All 8 Advanced Conditions
View All 34 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile